NewsPress ReleasesMediaOKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares15th September 2023OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares14th September 2023OKYO Pharma Limited Announces Withdrawal of Public Offering14th September 2023OKYO Pharma Announces Public Offering of Ordinary Shares13th September 2023OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease8th September 2023OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)30th August 2023OKYO Pharma Limited Regains Compliance with Nasdaq Listing Minimum Market Value Rule29th August 2023OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 202315th August 2023OKYO Pharma Limited Announces Withdrawal of Public Offering31st July 2023OKYO Pharma Announces Proposed Public Offering of Ordinary Shares28th July 2023OKYO Pharma Limited Receives Nasdaq Deficiency Notice28th July 2023OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center28th July 2023OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer27th July 2023OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease6th June 2023London Stock Exchange Delisting22nd May 2023Commencement of trading of new ordinary shares on The Nasdaq Capital Market19th May 2023Change of Record Time and Last Day of Dealings15th May 2023OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform11th May 2023Change of Delisting Date to 22 May 202311th May 2023Result of General Meeting3rd May 2023OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 20233rd May 2023OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease 2nd May 2023OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease25th April 2023NOTICE OF GENERAL MEETING AND PUBLICATION OF CIRCULAR5th April 2023NOTICE OF INTENTION TO DELIST FROM THE LONDON STOCK EXCHANGE4th April 2023OKYO Pharma Today Announces Director Acquires Shares30th March 2023OKYO Pharma Today Announces Director Acquires Shares29th March 2023OKYO Pharma Announces PDMR Dealing24th March 2023OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website. 16th March 2023Closing of Global Private Placement16th March 2023OKYO Pharma announces that the board of directors of the Company, acting on a recommendation of the Remuneration Committee has awarded options to directors and persons discharging managerial responsibility.15th March 2023OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management14th March 2023CEO of OKYO Pharma, Inc., Dr. Gary Jacob, Interviewed by Leading Publisher,SmallCapsDaily13th March 2023OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease28th February 2023World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma23rd February 2023Jay S. Pepose, MD, PhD, FARVO23rd February 2023OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.21st February 2023Allotment of Shares and Total Voting Rights14th February 2023Interim Results for the Six Months Ending 30 September 202230th December 2022OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease22nd December 2022OKYO to Participate at Biotech Showcase21st December 2022OKYO publicly files a registration statement with the SEC6th December 2022Change of Auditor1st December 2022Grant of options –PDMR dealing24th November 2022OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease21st November 2022OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease10th November 2022OKYO Pharma Ltd. Announces Participation in The ThinkEquity Conference20th October 2022OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®8th September 2022Result of Annual General Meeting7th September 2022OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm30th August 2022Notice of Annual General Meeting18th August 2022Final audited results for the year ended 31 March 202216th August 2022PDMR Dealing9th June 2022PDMR Dealing20th May 2022OKYO Pharma Limited Announces Closing of Public Offering and Nasdaq Listing19th May 2022PDMR Dealing18th May 2022OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation17th May 2022OKYO Pharma Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting27th April 2022Pedram Hamrah, MD, FRCS, FARVO7th April 2022Bernard Denoyer23rd March 2022John Brancaccio23rd March 2022Willy Simon23rd March 2022Napoleone Ferrara, MD23rd March 2022Keeren Shah23rd March 2022Raj Patil, PhD23rd March 2022Gary Jacob, PhD23rd March 2022Gabriele Cerrone22nd March 2022Hello world!20th March 2022OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States7th March 2022OKYO Pharma announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain23rd February 2022Conversion of CLNs, cashless exercise of Warrants, and issue of equity21st February 2022Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease15th February 2022Grant of options – Director and PDMR dealings1st February 2022PDMR Dealing27th January 2022OKYO Pharma Limited: Interim results for the six months to 30 September 202126th January 2022Issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease14th December 2021First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease13th December 2021OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis6th December 2021DIRECTORATE CHANGE1st December 2021Result of Annual General Meeting27th September 2021Notice of Annual General Meeting9th September 2021Grant of options – Director dealings1st September 2021Final audited results for the year ended 31 March 20212nd August 2021OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications29th June 2021DIRECTORATE CHANGE17th June 2021TR-1: Standard form for notification of major holdings12th May 2021Admission of additional shares to listing on the Official List and to trading on the London Stock Exchange and director dealing7th May 2021Prospectus Publication Announcement5th May 2021OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain28th April 2021OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer29th March 2021OKYO Pharma Limited CEO Gary Jacob tells Proactive’s Andrew Scott it’s time to take the company from development stage and into the clinic10th March 2021ISSUE OF EQUITY – UPDATE3rd March 2021ISSUE OF EQUITY1st March 2021OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation23rd February 2021OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS19th January 2021DIRECTORATE CHANGES AND PDMR DEALING7th January 2021Interim results for the six months to 30 September 202030th November 2020Upload of Articles of Association to National Storage Mechanism25th September 2020RESULT OF THE ANNUAL GENERAL MEETING25th September 2020Notice of Annual General Meeting9th September 2020Issue of convertible loan notes to raise an additional £500,0008th September 2020Grant of options – Director dealings21st August 2020Appointment of Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board19th August 2020Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ18th August 2020Final audited results for the year ended 31 March 202017th August 2020Dr James Khodabakhsh MD named Chairman of the SAB7th August 2020Holding(s) in Company6th August 2020Company Presentation3rd August 2020Upcoming Presentation31st July 2020Issue of convertible loan notes to raise £3,500,00028th July 2020DIRECTORATE CHANGE10th June 2020TR-1: Standard form for notification of major holdings5th June 2020Appointment of Broker3rd June 2020Issue of convertible loan notes to raise £440,00029th May 2020Balance of Placing to raise £560,000 announced on 23 March 202028th May 2020TR-1: Standard form for notification of major holdings27th May 2020TR-1: Standard form for notification of major holdings27th April 2020TR-1: Standard form for notification of major holdings30th March 2020Update on Placing to raise £560,00023rd March 2020Placing to raise £560,00019th March 2020Result of Annual General Meeting2nd March 2020DIRECTORATE CHANGE19th December 2019Interim results for the six months to 30 September 201929th November 2019OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease28th August 2019OKYO Pharma Announces Collaboration with Prof. Pedram Hamrah to Evaluate Proprietary Lead Compounds as Non-Opioid Analgesics Targeting G-Protein Coupled Receptors19th August 2019Final audited results for the year ended 31 March 20191st July 2019TR-1 – Notification of Major Holdings30th May 2019Result of General Meeting, Admission of Subscription Shares and Total Voting Rights20th May 2019Subscription of 36,363,636 new Ordinary Shares at a price of 1.1 pence per share to raise gross proceeds of £400,000 Proposed Approval of Waiver of the obligations under Rule 9 of the Takeover Code and Notice of General Meeting26th April 2019OKYO releases preclinical data on OKYO-0101 at the 14th Congress on Ocular Pharmacology and Therapeutics, 2019 demonstrating its potential to treat dry eye.14th March 2019Presentation of Preclinical Data Demonstrating Potential of OKYO-0101 for Dry Eye Treatment7th March 2019OKYO Pharma Corporate Update23rd January 2019Interim results for the six months to 30 September 201830th November 2018Expected Admission Date for Consideration Shares1st November 2018Allotment of ordinary shares and listing application24th October 2018OKYO Pharma sees big opportunities for its dry eye and pain management technology12th September 2018Result of AGM6th September 2018Notification of Major Holdings22nd August 2018
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares15th September 2023
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares14th September 2023
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease8th September 2023
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)30th August 2023
OKYO Pharma Limited Reports Annual Results for the Twelve Months Ended March 31, 202315th August 2023
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center28th July 2023
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease6th June 2023
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 20233rd May 2023
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease 2nd May 2023
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease25th April 2023
OKYO Pharma Announces Phase 2 Trial of OK-101 Drug to Treat Dry Eye Disease is now listed on the ClinicalTrials.gov Public Website. 16th March 2023
OKYO Pharma announces that the board of directors of the Company, acting on a recommendation of the Remuneration Committee has awarded options to directors and persons discharging managerial responsibility.15th March 2023
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement and investment by directors and members of senior management14th March 2023
CEO of OKYO Pharma, Inc., Dr. Gary Jacob, Interviewed by Leading Publisher,SmallCapsDaily13th March 2023
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease28th February 2023
World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma23rd February 2023
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on February 21-23, 2023.21st February 2023
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease22nd December 2022
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease21st November 2022
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease10th November 2022
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®8th September 2022
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm30th August 2022
OKYO Pharma Limited Announces Pricing of Initial Public Offering of ADSs in the U.S. with director participation17th May 2022
OKYO Pharma Announces Two Presentations at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting27th April 2022
OKYO publicly files a registration statement with the SEC for a proposed dual-listing on the Nasdaq Capital Market and Offering in the United States7th March 2022
OKYO Pharma announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain23rd February 2022
Successful Completion of a Pre-IND Meeting with the FDA on the Development of OK-101 to Treat Dry Eye Disease15th February 2022
Issuance of U.S. Patent No. 11,197,906 covering OKYO Pharma’s drug candidate OK-101 for use to treat dry eye disease14th December 2021
First-in-Class Drug Candidate OK-101 Displaying Both Anti-inflammatory and Ocular Pain-Reducing Potential to Treat Dry Eye Disease13th December 2021
OKYO to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease (“DED”) and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis6th December 2021
OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications29th June 2021
Admission of additional shares to listing on the Official List and to trading on the London Stock Exchange and director dealing7th May 2021
OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain28th April 2021
OKYO Pharma Limited CEO Gary Jacob tells Proactive’s Andrew Scott it’s time to take the company from development stage and into the clinic10th March 2021
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation23rd February 2021
OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS19th January 2021
Issue of additional convertible loan notes to raise £1,437,104 and intention to seek dual listing on NASDAQ18th August 2020
OKYO Pharma Announces Potent Anti-inflammatory Effects of OK-113, a Novel Agonist of Chemerin G-Protein Coupled Receptor, in a Mouse Model of Dry Eye Disease28th August 2019
OKYO Pharma Announces Collaboration with Prof. Pedram Hamrah to Evaluate Proprietary Lead Compounds as Non-Opioid Analgesics Targeting G-Protein Coupled Receptors19th August 2019
Subscription of 36,363,636 new Ordinary Shares at a price of 1.1 pence per share to raise gross proceeds of £400,000 Proposed Approval of Waiver of the obligations under Rule 9 of the Takeover Code and Notice of General Meeting26th April 2019
OKYO releases preclinical data on OKYO-0101 at the 14th Congress on Ocular Pharmacology and Therapeutics, 2019 demonstrating its potential to treat dry eye.14th March 2019
Presentation of Preclinical Data Demonstrating Potential of OKYO-0101 for Dry Eye Treatment7th March 2019
